ABCA4 and retinal disorder: There is an ongoing extension phase-2 CT examining the tolerability and effects of ALK-001 on Stargardt disease (TEASE), with 140 patients affected by ABCA4-associated retinopathy (NCT04239625), and another CT is in the recruiting phase (NCT02402660).